TRT and hCG: How the hCG Protocol Works and Where to Get It (2026 Guide)

Executive Summary

Most men starting testosterone replacement therapy focus on one number: their serum testosterone. That is understandable — it is the number that drives their symptoms. But serum testosterone and intratesticular testosterone (ITT) are not the same thing, and the difference matters enormously for anyone who cares about testicular function, fertility, or physical side effects like atrophy. ITT — the testosterone concentration inside your testes — runs approximately 70–100 times higher than serum testosterone. That local concentration is not just a curiosity; it is required for spermatogenesis. When you add exogenous testosterone through TRT, your pituitary detects high circulating levels and stops secreting LH. Without LH, your Leydig cells stop producing testosterone locally. The result is that your blood testosterone rises from the external source while your intratesticular testosterone collapses. Atrophy follows. Sperm production falls. For men who care about those outcomes, this is a solvable problem — but the solution requires proactive protocol design, not a hope that it won't happen to you.

That solution is human chorionic gonadotropin (hCG). hCG is an LH analog: it binds to the same receptor that LH binds to on Leydig cells in the testes and directly stimulates testosterone production, bypassing the pituitary shutdown entirely. When given at the right dose alongside TRT, hCG maintains intratesticular testosterone near normal levels, preserves testicular volume, and sustains spermatogenesis — even while exogenous testosterone has shut down the HPT axis at every upstream level. For fertility-conscious men, it is the primary intervention between 'start TRT' and 'lose your fertility options.' For men not focused on fertility, the benefits are more subjective but real for many: maintained testicular size, and what some describe as better overall hormonal balance or mood stability when the testes remain metabolically active.

The catch in 2026 is availability. The FDA ruling in 2020 that removed hCG from the list of bulk drug substances eligible for compounding created genuine pharmacy disruption. Some providers pivoted to FDA-approved commercial hCG (Pregnyl, Novarel). Others moved to gonadorelin — a GnRH analog that stimulates the pituitary to release LH naturally, producing a similar ITT-maintenance effect through a different upstream mechanism. Not every clinic prescribes either. Consumer telehealth platforms often default to the simplest compliant TRT protocol, which does not include hCG or gonadorelin. This guide covers everything you need to know: the clinical mechanism and evidence, the 2026 availability picture, standard dosing, which online TRT providers actually include this in their protocol toolkit, and the decision framework for whether you actually need it. For the fertility-specific context, read TRT and fertility. For the broader treatment-choice question, see enclomiphene vs. TRT.

At-a-Glance Comparison

Protocol options for men on TRT who want to preserve testicular function, fertility, or intratesticular testosterone. hCG and gonadorelin are adjuncts to TRT, not replacements. Enclomiphene is a TRT alternative for secondary hypogonadism only. Updated March 2026.

Why ITT Matters: The Problem hCG Solves on TRT

Serum testosterone from TRT rises because you are adding testosterone from an external source. But that rising serum level tells your brain to cut off the signal chain that was driving your testes — which means intratesticular testosterone (ITT), the concentration inside the testes themselves, collapses even while your blood test looks good. Most TRT clinics don't explain this distinction clearly, but it's the entire reason hCG exists as an adjunct. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The hypothalamic-pituitary-testicular (HPT) axis operates as a feedback loop. Your hypothalamus releases GnRH → pituitary releases LH and FSH → LH stimulates Leydig cells in the testes to produce testosterone locally → FSH drives Sertoli cells to support spermatogenesis. When exogenous testosterone from TRT raises serum levels, the hypothalamus and pituitary detect the signal and dramatically reduce GnRH, LH, and FSH output. The testes receive no LH signal, so Leydig cells stop producing testosterone locally. ITT — which normally runs 70–100x higher than serum testosterone — drops to near-zero. Spermatogenesis depends on that local testosterone concentration, not serum levels, which is why men on TRT without any adjunct typically develop severe oligospermia or azoospermia within 3–4 months even when their blood testosterone looks excellent. Testicular atrophy is the visible consequence of this mechanism. Without ongoing LH stimulation, testicular size and weight decrease — a result of Leydig cell downregulation and reduced intratesticular activity. Studies using testicular ultrasound have documented measurable volume reduction within months of starting TRT without hCG. The severity varies by individual but is broadly correlated with ITT suppression depth. This is not a cosmetic issue for some men — it is a significant quality-of-life concern that influences adherence and protocol satisfaction. The clinical intervention that addresses all of this is remarkably targeted: give the testes a direct LH-receptor signal that bypasses the now-silenced pituitary entirely. That is what hCG does. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common underestimation is that this happens 'slowly' or 'later.' Testicular atrophy and ITT suppression begin within weeks of starting TRT and progress over months. Men who start TRT with the assumption that fertility can be 'dealt with later' often discover at month 4 that their sperm count has already reached zero. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How hCG Works: The LH Analog Mechanism and Clinical Evidence

hCG is not a testosterone compound — it is a glycoprotein hormone that binds to LH receptors on Leydig cells and directly stimulates local testosterone production inside the testes. The clinical evidence for its effectiveness at maintaining ITT while on TRT is well-established and unusually consistent across study designs. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Human chorionic gonadotropin shares structural homology with luteinizing hormone at the receptor level: both bind the LHCGR receptor on Leydig cells and activate adenylyl cyclase → cAMP → StAR protein → cholesterol conversion → testosterone synthesis. This is why hCG can directly maintain ITT even when pituitary LH output is fully suppressed by exogenous testosterone. The pivotal study establishing dose ranges is Coviello et al. (2005, JCEM): men on testosterone enanthate were randomized to placebo or hCG at 125, 250, or 500 IU every other day. The 250 IU and 500 IU groups maintained ITT near pre-treatment levels — 7.2 and 7.9 ng/mL respectively, versus 1.0 ng/mL in the TRT-only group. Critically, the 500 IU group showed numerically better ITT maintenance with no meaningful increase in side effects at that study's monitoring window. A 2007 follow-up by Depenbusch and colleagues confirmed that low-dose hCG (200–500 IU every other day or 3x/week) was sufficient to prevent ITT suppression during TRT without triggering significant estradiol elevation at the lower end of the dose range. The mechanism behind the estradiol caveat: hCG stimulates not only testosterone production in Leydig cells but also aromatase activity inside the testes — producing intratesticular estrogen alongside testosterone. At higher doses (1,000+ IU), this intratesticular estrogen elevation can produce systemic estrogen effects (water retention, mood changes, nipple sensitivity) that exceed what standard aromatase inhibitor dosing controls for. This is why 250–500 IU every other day is the standard fertility-preservation dose, not 1,000+ IU. For fertility-recovery protocols in already-azoospermic TRT users: higher doses (1,500–2,000 IU every other day + FSH adjunct or clomiphene) are sometimes used under specialist management to restart spermatogenesis — but that is a different clinical scenario from prevention. For prevention, the low-dose protocol is the standard, and the evidence supports it. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: hCG increases intratesticular estrogen production alongside testosterone. Men who add hCG without monitoring sensitive estradiol and adjusting aromatase inhibitor use accordingly can develop elevated estradiol symptoms (water retention, mood changes, reduced libido paradoxically) that are often misattributed to the TRT itself. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

hCG Availability in 2026: The Compounding Change and Gonadorelin

In 2020, the FDA removed hCG from the bulk drug substance list for compounding, which meant compounding pharmacies could no longer produce the low-cost compounded hCG that most TRT clinics had been using. The regulatory change created genuine availability friction that still shapes the market in 2026. Understanding what replaced it — and what hasn't — is practically important for men evaluating TRT protocols. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Before 2020, most TRT clinics prescribed compounded hCG at $20–$40/month from 503A compounding pharmacies, often in multi-use vials. That low-cost sourcing pathway ended with the FDA's final decision that hCG is a biologically complex substance requiring full drug approval processes, not compounding discretion. Clinics responded in two ways: (1) pivoting to FDA-approved commercial hCG — Pregnyl (Organon) and Novarel (Ferring) are the primary brands — which remains fully available by prescription but at a higher price point ($50–$90/vial at most retail pharmacies, depending on insurance). Prescription hCG through a TRT clinic is still accessible but is now a discrete cost line rather than a bundled add-on at $25/month. (2) Migrating to gonadorelin, a synthetic GnRH analog (also called GnRH pulse therapy in fertility contexts). Gonadorelin stimulates the pituitary to release LH and FSH naturally — achieving the downstream ITT-maintenance effect through an upstream mechanism. Because gonadorelin is peptide-based and not on the same exclusion list, it can be compounded by 503A pharmacies and remains a relatively low-cost option ($30–$60/month at most compounding pharmacies). Maximus Tribe has publicly adopted gonadorelin as their preferred hCG alternative in TRT protocols. Defy Medical continues to offer both commercial hCG and gonadorelin. The practical difference for patients: hCG acts directly on Leydig cells and works regardless of whether your pituitary is functional. Gonadorelin requires your pituitary to respond — if long-term TRT has rendered your pituitary significantly less responsive, gonadorelin may be less reliable at fully restoring LH pulse amplitude. For the vast majority of men on standard TRT doses, this distinction is clinical theory rather than practical problem. Both options maintain ITT meaningfully better than TRT without any adjunct. The larger practical factor is which one your clinic can actually prescribe and which pharmacy can dispense it affordably in your state. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men researching hCG for TRT online often find outdated protocol information that still cites compounded hCG at $20–$40/month. That pricing mostly reflects pre-2020 compounding access. Setting realistic cost expectations for commercial hCG or gonadorelin before enrollment avoids sticker shock during treatment. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Standard Protocol: Dosing, Timing, and Monitoring

The standard TRT + hCG protocol for fertility preservation is well-defined in the clinical literature and practiced consistently at specialist TRT clinics. The dosing window, monitoring cadence, and adjustment logic are not ambiguous — knowing them before you speak to a clinic makes you a better advocate for your own protocol. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The standard fertility-preservation hCG protocol is: 250–500 IU every other day (EOD), injected subcutaneously, co-administered with your TRT protocol. Some clinics use twice-weekly (250 IU on Monday and Thursday, for example) rather than strict EOD for adherence simplicity — the total weekly dose (350–1,000 IU/week in the prevention range) is what matters more than the precise interval. Injection site: subcutaneous (abdomen, lateral thigh) using an insulin syringe (29–31g, 0.5–1cc). hCG is stable in solution for 30–60 days refrigerated once reconstituted from lyophilized powder. Gonadorelin protocol: typically 100–200 mcg subcutaneous injection 2–3x/week. Gonadorelin has a much shorter half-life than hCG (minutes versus hours) and must be dosed more frequently for sustained ITT effect. Some protocols use daily low-dose gonadorelin injections. Monitoring additions when hCG or gonadorelin is added to TRT: Sensitive estradiol (Quest Diagnostics LC/MS-MS or equivalent) at 6 weeks and every 3 months thereafter. Standard follow-up panel: total testosterone, free testosterone, LH (will be suppressed even on hCG — this is expected), sensitive estradiol, hematocrit, PSA. If fertility is the goal: add semen analysis at 3 and 6 months. Typical results with the standard prevention protocol: ITT maintained near pre-TRT levels (Coviello data), no significant increase in serum estradiol at 250 IU dose, spermatogenesis maintained in most (not all) men. What does not work: very-low-dose hCG (100 IU EOD or less) has been shown in Coviello's data to NOT adequately maintain ITT — the 125 IU group did not perform significantly better than placebo for ITT preservation. Do not let a clinic talk you into a sub-therapeutic 'starter dose' that will not achieve the outcome you want. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Under-dosing hCG is the most common protocol error at clinics that prescribe it reluctantly or defensively. 125 IU EOD or less will not reliably maintain ITT. 250–500 IU EOD is the minimum effective range from the clinical data. Always confirm the specific dose, not just whether hCG is 'included.' Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Which Online TRT Clinics Prescribe hCG or Gonadorelin in 2026

Not all TRT clinics are equally equipped or willing to prescribe hCG adjunct protocols. Consumer telehealth platforms optimized for frictionless enrollment often default to standard testosterone-only protocols. Specialist clinics designed for protocol customization are more likely to include hCG or gonadorelin in their standard or add-on toolkit. Knowing where each major platform stands before you enroll is better than discovering this limitation at month three. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Here is how the major online TRT providers currently approach hCG and gonadorelin adjunct prescribing: Defy Medical is the strongest option for hCG-inclusive TRT. Their specialist-model approach is built for complex protocols — TRT + hCG + anastrozole management is a standard Defy protocol, not an edge case. They use both commercial hCG and gonadorelin depending on case and state. All-in cost for TRT + hCG protocol at Defy typically runs $200–$450/month depending on medication complexity and lab cadence. Best for: men who need the deepest protocol customization, complex hormonal profiles, or fertility-specific management. Maximus Tribe has publicly transitioned to gonadorelin as their preferred hCG alternative and includes it as a TRT add-on. Their at-home lab model and physician-led protocol design make them a practical mid-tier option for men who want gonadorelin without the full specialist cost of Defy. Monthly cost for TRT + gonadorelin at Maximus is approximately $150–$250/month all-in. Marek Health takes a functional medicine approach and supports TRT + hCG protocols with deep monitoring depth. Lab costs run higher ($450–$1,700 upfront for full panels; $150–$300/month ongoing), but the clinical model is equipped for fertility-conscious protocols. TRT Nation is a budget TRT provider (testosterone cypionate at ~$35–$50/month) with limited add-on protocol support. hCG adjunct is not a standard offering; some patients have reported success requesting it, but clinical depth for ongoing management is lower than Defy or Maximus. Hims and Roman are primarily consumer telehealth platforms focused on frictionless enrollment. Their standard TRT protocols (Kyzatrex oral testosterone for Hims; testosterone cypionate injections for Roman) do not typically include hCG or gonadorelin as default add-ons. If fertility preservation is a priority, these platforms are not the right clinical match without extensive out-of-scope protocol negotiation. For a full provider comparison including consultation model, monitoring depth, and pricing, use compare providers and see best online TRT clinics compared. For the specific Hims/Roman/Maximus breakdown, see Hims vs. Roman vs. Maximus TRT comparison. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The biggest clinical mismatch: men who want hCG or gonadorelin adjunct on TRT and enroll with Hims or Roman without confirming protocol availability. These platforms are excellent for straightforward TRT delivery but are not designed for complex protocol customization. Finding this out after month two means restarting the enrollment and qualification process elsewhere. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Do You Actually Need hCG? A Decision Framework for Men Starting TRT

hCG and gonadorelin add cost, injection complexity, and monitoring requirements to your protocol. Not every man on TRT needs them. The decision should be driven by your specific clinical profile and priorities — not by a blanket 'hCG is always better' or 'you don't need it' default from a telehealth intake form. Buyers searching for hcg on trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Use this framework to determine whether hCG (or gonadorelin, or enclomiphene) belongs in your protocol: Question 1: Do you want biological children now or within the next 2–3 years? If yes — hCG adjunct from day one, or enclomiphene if your LH/FSH pattern confirms secondary hypogonadism. TRT without any adjunct is not appropriate for this profile. Question 2: Does testicular atrophy concern you? If testicular volume reduction would significantly affect your quality of life or self-image — hCG is indicated. It is the most reliable way to maintain testicular stimulation and prevent progressive volume reduction. Question 3: Is your testosterone severely deficient and primary hypogonadism confirmed (elevated LH/FSH)? If yes — TRT is necessary. hCG cannot raise testosterone meaningfully in primary hypogonadism (the testes are maximally stimulated already). The hCG value here is atrophy prevention and ITT maintenance, not testosterone augmentation — still valuable, but different rationale. Question 4: Are you willing to add injections and $30–$100/month to your protocol? If no — TRT alone may be the pragmatic choice. Some men prefer the simplicity of a single injection and are not concerned about the downstream effects that hCG prevents. That is a legitimate patient preference, not a protocol failure. Question 5: Do you have secondary hypogonadism (low/normal LH/FSH + low T) and active fertility goals? Consider enclomiphene instead of TRT + hCG entirely. Enclomiphene raises testosterone by stimulating your own axis without suppressing it, which avoids the need for hCG adjunct altogether. See enclomiphene vs. TRT and best online enclomiphene clinics 2026 for that pathway. Bottom line: hCG or gonadorelin on TRT is appropriate for men with any fertility concern, significant concern about testicular atrophy, or who want a more complete hormonal protocol than testosterone-only. It is optional — not universal — but is often under-discussed at consumer telehealth platforms that default to the simplest protocol. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men who skip hCG because 'I don't plan on having kids' but do care about testicular volume are making a decision based on one factor (fertility) when atrophy prevention is a separate and independent reason to add the adjunct. These are distinct clinical considerations — make sure you're evaluating both. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If fertility, testicular volume, or a complete hormonal protocol matters to you, hCG or gonadorelin belongs in your TRT plan — but you need a clinic that actually prescribes it. Compare providers by protocol depth, not just price. Use our provider comparison tool to find one that fits your specific goals.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What does hCG do when you're on TRT?

hCG acts as an LH analog — it binds to LH receptors on Leydig cells in the testes and directly stimulates testosterone production inside the testes, even when your pituitary has stopped secreting LH due to exogenous testosterone. This maintains intratesticular testosterone (ITT) near normal levels, prevents testicular atrophy, and preserves the spermatogenesis machinery. hCG does not raise your serum testosterone significantly on top of TRT — its value is local testicular function, not blood level augmentation.

Is hCG necessary on TRT?

hCG or gonadorelin is necessary if: you want to preserve fertility options while on TRT, testicular atrophy is a concern, or you want a more complete hormonal protocol that maintains intratesticular testosterone. It is not medically necessary for men with no fertility goals who are not concerned about testicular volume changes. It adds cost and injection complexity — some men prefer the simplicity of testosterone-only protocols and accept the downstream trade-offs.

What is the standard hCG dose for men on TRT?

The standard fertility-preservation dose established by Coviello et al. (2005, JCEM) is 250–500 IU every other day (EOD), injected subcutaneously. Both doses maintained intratesticular testosterone near pre-treatment levels. The 125 IU dose did not adequately maintain ITT in that study. Some clinics use 250 IU twice weekly rather than strict EOD — total weekly dose of 500–1,000 IU is the relevant metric for prevention protocols.

What is gonadorelin and is it as effective as hCG for TRT?

Gonadorelin is a synthetic GnRH analog that stimulates your pituitary to release LH naturally — achieving ITT maintenance through an upstream mechanism rather than by directly stimulating Leydig cells (as hCG does). It became a popular hCG alternative after the FDA's 2020 compounding change restricted low-cost compounded hCG. For most men on standard TRT doses, gonadorelin achieves similar ITT maintenance outcomes. The practical differences: gonadorelin requires a more responsive pituitary and has a shorter half-life, requiring more frequent dosing (typically 100–200 mcg 2–3x/week). hCG is more direct and has a longer action window per dose.

Does hCG on TRT help with testicular atrophy?

Yes — this is one of the primary clinical use cases. Without LH stimulation (which TRT suppresses), Leydig cells downregulate and testicular volume decreases. hCG restores the LH-receptor signal, keeps Leydig cells active, and prevents progressive atrophy. Starting hCG before significant atrophy occurs is more effective than trying to reverse existing volume loss — prevention is the stronger use case.

Can I get hCG prescribed through an online TRT clinic?

Yes — but not at every clinic. Defy Medical and Maximus Tribe both offer hCG or gonadorelin as TRT adjuncts. Defy Medical uses commercial hCG (Pregnyl/Novarel) and gonadorelin; Maximus uses gonadorelin as their preferred option. Consumer telehealth platforms like Hims and Roman typically do not include hCG or gonadorelin in standard TRT protocols. Marek Health and TRT Nation have variable hCG support. Always confirm directly before enrolling.

How much does hCG add to TRT cost?

Commercial hCG (Pregnyl or Novarel) typically adds $50–$100/month depending on your pharmacy and dose. Compounded gonadorelin typically adds $30–$75/month. These costs are in addition to your base TRT medications, lab work, and consultation fees. Total all-in for TRT + hCG or gonadorelin at clinics like Maximus ranges from $150–$250/month; at Defy Medical $200–$450/month.

Will hCG on TRT help my sperm count?

For fertility prevention (starting hCG from the beginning of TRT), yes — clinical evidence shows the standard 250–500 IU EOD dose maintains ITT and spermatogenesis in most men. For fertility recovery (adding hCG after azoospermia has already developed), the evidence is more variable: a 2024 Fertility and Sterility study found hCG at higher doses (5,000 IU 3x/week) led to conception in about 27% of men in the study period, but persistent pituitary suppression remained in some patients at 6 months. Recovery outcomes depend on duration of prior TRT use, individual biology, and the specific protocol used.

Should I use hCG or enclomiphene?

It depends entirely on your diagnosis. Enclomiphene is a SERM that stimulates your own HPT axis — it only works in secondary hypogonadism (low/normal LH/FSH + low T). If your testes can respond to stimulation, enclomiphene raises testosterone while fully preserving HPT axis function and fertility. hCG is an adjunct to TRT — appropriate for any hypogonadism type (primary or secondary) when you are already committed to exogenous testosterone but want to protect ITT and fertility. The decision starts with your LH and FSH panel. See the full breakdown in enclomiphene vs. TRT.

Does TRT with hCG affect estrogen levels?

hCG stimulates intratesticular aromatase alongside testosterone production, which can increase estradiol levels beyond what TRT alone would produce. At standard prevention doses (250–500 IU EOD), estradiol elevation is typically modest and manageable. At higher recovery doses (1,000+ IU EOD), estradiol elevation is more significant and may require aromatase inhibitor adjustment. Adding sensitive estradiol (LC/MS-MS) to your monitoring panel at 6 weeks and every 3 months thereafter is standard protocol management when hCG is included.